Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands
Files
Publication date
2020-03-28
Authors
Woestenberg, Petra J.
King, Audrey J.
Van Benthem, Birgit H.B.
Leussink, Suzan
van der Sande, Marianne A B
Hoebe, Christian J.P.A.
Bogaards, Johannes A.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.
Keywords
Anal cancer, Human papillomavirus (HPV), Human papillomavirus vaccine, Public health, Vaccine effectiveness, Taverne, General Medicine
Citation
Woestenberg, P J, King, A J, Van Benthem, B H B, Leussink, S, Van Der Sande, M A B, Hoebe, C J P A & Bogaards, J A 2020, 'Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands', Journal of Infectious Diseases, vol. 221, no. 8, pp. 1280-1285. https://doi.org/10.1093/infdis/jiz187